Vertex Earnings: Strong Demand for Trikafta/Kaftrio Drives Sales; Pipeline Continues to Make Progress
Vertex reported third-quarter results highlighted by strong uptake of its cystic fibrosis triple combination therapy, Trikafta/Kaftrio, in the United States and internationally. Quarterly product revenue of $2.48 billion represented a 6% increase from the prior-year period. Vertex’s results are tracking our expectations, and we maintain our fair value estimate of $314 per share.